Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Insights+ Key Biosimilars Events of July 2022
Insights+ Key Biosimilars Events of July 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of July, Polpharma Biologics reported EMA's acceptance of MAA…
August 4, 2022
Disease of the Month: Hepatitis - D Disease
Disease of the Month: Hepatitis – D Disease
Hepatitis D is a liver infection caused by the Hepatitis D virus (HDV) which causes the liver to become inflamed. It is also known by name of Hepatitis Delta virus or Delta Hepatitis1. Hepatitis D is a double infection as HDV requires the Hepatitis B virus (HBV) to replicate itself, therefore in the absence of…
July 28, 2022
Top Performing Drug of 2021 - Eliquis (July Edition)
Top Performing Drug of 2021 – Eliquis (July Edition)
Active Ingredients: Apixaban Strength: 2.5 mg and 5 mg Dosage Form: Tablet Mechanism of Action: Factor Xa inhibitors First Approval: US (Dec 28, 2012), EU (May 18, 2011) Revenue1 Eliquis is a leading novel oral anticoagulant of BMS. The revenue for BMS continued to grow due to Eliquis and other recently launched new products. BMS and Pfizer jointly develop and…
July 28, 2022
Insights+ The US FDA New Drug Approvals in June 2022
Insights+: The US FDA New Drug Approvals in June 2022
The US FDA approved 2 NDAs and 2 BLA in June 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 37 novel products in 2022 In June 2022, the major highlights drugs were Amvuttra's approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis, Skyrizi for active Crohn's disease, Olumiant…
July 21, 2022
Insights+ Key Biosimilars Events of June 2022
Insights+ Key Biosimilars Events of June 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of June, Organon entered into an agreement with Henlius…
July 7, 2022
PharmaShots' Key Highlights of Second Quarter 2022
PharmaShots’ Key Highlights of Second Quarter 2022
The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fraction Starting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…
June 30, 2022
Disease of the Month: Vitiligo Disease
Disease of the Month: Vitiligo Disease
25th June is celebrated as Vitiligo Awareness Day. Vitiligo is a long-term skin disorder in which skin loses its color and white patches develop on the skin. It can occur in any part of the body and the discolored area grows with time. If the affected white area is less than 5mm it is known as macules…
June 25, 2022
Top Performing Drug of 2021 - Revlimid (June Edition)
Top Performing Drug of 2021 – Revlimid (June Edition)
Active Ingredients: Lenalidomide Strength: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg Dosage Form: Capsules Mechanism of Action: Angiogenic inhibitor First Approval: US (Dec 27, 2005), EU (14 Jun, 2007) Revenue Revlimid (lenalidomide) is one of the key products of Bristol-Myers Squibb (BMS) that represent a significant percentage of the company’s total revenue. Sales of…
June 23, 2022
Insights+ The US FDA New Drug Approvals in May 2022
Insights+: The US FDA New Drug Approvals in May 2022
The US FDA has approved 7 NDAs in May 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 33 novel products in 2022 In May 2022, the major highlights drugs were Lilly's Mounjaro (tirzepatide) received the US FDA’s approval for the treatment of adults with Type 2…
June 16, 2022
Insights+ Key Biosimilars Events of May 2022
Insights+ Key Biosimilars Events of May 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, JSR Life Sciences launches Similis Bio business…
June 2, 2022
Load more